Indication intelligence, analysis and sector perception

RegMed Investors (RMi) - Q1/22 Cell and Gene Therapy Earnings Scorecard Results

May 16, 2022

A scorecard of earnings releases of covered companies - 31 of 35 - so far The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status". 5/16 adding Brainstorm Cell Therapeutics (BCLI), Homology Medicine FIXX) and Biostage (BSTG)  

RegMed Investors: The week that will define the cell and gene therapy sector’s share pricing month

May 3, 2022

Earnings’ today – uniQure NV (QURE) – below with more this week … Sage Therapeutics (SAGE) on 5/3, AxoGen (AXGN), Fate Therapeutics (FATE), Global Blood Therapeutics (GBT), Ionis Pharmaceuticals (IONS), MiMedx (MDXG), Editas Medicine (EDIT) and Vericel (VCEL) on 5/4; Sangamo Therapeutics (SGMO) and Ultragenyx Pharmaceuticals (RARE),  Intellia Therapeutics (NTLA) on 4/5, BioLife Solutions (BLFS) on 5/9, Agenus (AGEN) on 5/10 and Brainstorm Cell Therapeutics (BCLI) on 5/16 so far.  

The Biostage (BSTG) Chronicles: Surgeon on trial in Sweden over experimental windpipe transplants

April 28, 2022

BSTG is also ensnared with a terminal death suit involving Paolo Macchiarini An Italian doctor who made headlines for pioneering windpipe surgery has gone on trial in Sweden, charged with aggravated assault for performing the experimental procedure.